Uustare Ain, Vonk Argo, Terasmaa Anton, Fuxe Kjell, Rinken Ago
Institute of Organic and Bioorganic Chemistry, University of Tartu, Jakobi Str. 2, EE-51014 Tartu, Estonia.
Life Sci. 2005 Feb 11;76(13):1513-26. doi: 10.1016/j.lfs.2004.10.027. Epub 2004 Dec 19.
We have characterized the binding of [2-(3)H]-4-(2-[7-Amino-2-(2-furyl)-[1,2,4]-triazolo-[2,3-a]-[1,3,5]-triazin-5-ylamino]ethyl)phenol ([(3)H]ZM241385) to adenosine A(2A) receptors in membranes of rat striatum and transfected CHO cells. Saturation experiments showed that [(3)H]ZM241385 binds to a single class of binding sites with high affinity (K(d) = 0.23 nM and 0.14 nM in CHO cell and striatal membranes, respectively). The membranes of CHO cells required pretreatment with adenosine deaminase (ADA) to achieve high-affinity binding, while ADA had no influence on the ligand binding properties in striatal membranes. The binding of [(3)H]ZM241385 was fast and reversible, achieving equilibrium within 20 minutes at all radioligand concentrations. The kinetic analysis of the [(3)H]ZM241385 interaction with A(2A) receptors indicated that the reaction had at least two subsequent steps. The first step corresponds to a fast equilibrium, which also determines the antagonist potency to competitively inhibit CGS21680-induced accumulation of cAMP (first equilibrium constant K(A) = 6.6 nM). The second step corresponds to a slow process of conformational isomerization (equilibrium constant K(i) = 0.03). The combination of the two steps gives the dissociation constant K(d) = 0.20 nM based on the kinetic data, which is in good agreement with the directly measured value. The data obtained shed light on the mechanism of the [(3)H]ZM241385 interaction with adenosine A(2A) receptors from different sources in vitro. The isomerization step of the A(2A) antagonist radioligand binding has to be taken into account for the interpretation of the binding parameters obtained from the various competition assays and explain the discrepancy between antagonist affinity in saturation experiments versus its potency in functional assays.
我们已对[2-(³H)-4-(2-[7-氨基-2-(2-呋喃基)-[1,2,4]-三唑并-[2,3-a]-[1,3,5]-三嗪-5-基氨基]乙基)苯酚([(³H]ZM241385)]与大鼠纹状体膜和转染的CHO细胞膜中腺苷A₂A受体的结合进行了表征。饱和实验表明,[(³H]ZM241385以高亲和力结合到单一类别的结合位点(在CHO细胞和纹状体膜中,Kd分别为0.23 nM和0.14 nM)。CHO细胞膜需要用腺苷脱氨酶(ADA)预处理以实现高亲和力结合,而ADA对纹状体膜中的配体结合特性没有影响。[(³H]ZM241385的结合快速且可逆,在所有放射性配体浓度下20分钟内达到平衡。[(³H]ZM241385与A₂A受体相互作用的动力学分析表明,该反应至少有两个后续步骤。第一步对应快速平衡,这也决定了拮抗剂竞争性抑制CGS21680诱导的cAMP积累的效力(第一个平衡常数K(A)=6.6 nM)。第二步对应构象异构化的缓慢过程(平衡常数K(i)=0.03)。基于动力学数据,这两个步骤的组合给出解离常数Kd = 0.20 nM,与直接测量值非常吻合。所获得的数据揭示了[(³H]ZM241385在体外与不同来源的腺苷A₂A受体相互作用的机制。在解释从各种竞争试验获得的结合参数时,必须考虑A₂A拮抗剂放射性配体结合的异构化步骤,并解释饱和实验中拮抗剂亲和力与其在功能试验中效力之间的差异。